Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Lymph nodes: where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.
October 6, 2021 ||
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
The first patient was dosed at MD Anderson as part of a multicenter clinical trial to evaluate the safety and efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine, in patients with KRAS-driven tumors. » Read more
September 22, 2021 ||
Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit, being held virtually on September 20-22, 2021. » Read more
Orchestrating the immune system for precision immunity — Download this articleto see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.